Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.
A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.
National Institute for Biological Standards and Control, South Mimms, Potters Bar, Herts, UK. pminor@nibsc.ac.uk
Philip D
PD
Minor
Othmar G
OG
Engelhardt
John M
JM
Wood
James S
JS
Robertson
Simone
S
Blayer
Tony
T
Colegate
Luc
L
Fabry
Jacco G M
JG
Heldens
Yoichiro
Y
Kino
Otfried
O
Kistner
Ronald
R
Kompier
Keiichi
K
Makizumi
Jeroen
J
Medema
Shigetaka
S
Mimori
David
D
Ryan
Richard
R
Schwartz
Jonathan S B
JS
Smith
Keishin
K
Sugawara
Heidi
H
Trusheim
Theodore F
TF
Tsai
Ryoko
R
Krause
D017277:Drug Approval; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D009975:Orthomyxoviridae / Q000235:genetics / Q000254:growth & development* / Q000276:immunology*; D016865:Reassortant Viruses / Q000235:genetics / Q000254:growth & development* / Q000276:immunology*; D006113:United Kingdom; D014776:Virus Cultivation / Q000379:methods
D007252:Influenza Vaccines